Armata Pharmaceuticals (ARMP) Stock Analysis: AI Score & Alternative Data
ARMP alt-data: headcount climbing, web traffic lagging
Is Armata Pharmaceuticals a buy right now? The alternative data says hold. This ARMP stock analysis is built on the 25+ alternative data signals AltIndex tracks on Armata Pharmaceuticals every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 46/100: a Hold. The stock trades at $5.38 with a $200M market cap.
The bullish side of the 90-day ledger: headcount (according to LinkedIn) up 5.7% to 74 employees. The drag: web traffic down 30.3% to 4K monthly visits, and just 24% of employees report a positive business outlook. That tension is what keeps the score mid-range.
ARMP’s broader alt-data profile also covers sentiment (100/100). Every signal links to its own page with full history, the ARMP technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on ARMP is just below.
Armata Pharmaceuticals AI Stock Analysis
Armata Pharmaceuticals is a biotechnology company focused on treating antibiotic-resistant infections using bacteriophage-based therapies. With an innovative approach that taps into the natural antiviral properties of bacteriophages, Armata is pioneering new frontiers in medical treatments for chronic infections.
Analysis generated August 31, 2026.
Recent Armata Pharmaceuticals Stock Alerts
|
Armata Pharmaceuticals | September 11 Price is up by 6.1% in the last 24h. |
|
Armata Pharmaceuticals | September 10 Price is up by 6.1% in the last 24h. |
|
Armata Pharmaceuticals | September 9 Price is down by -6.2% in the last 24h. |
|
Armata Pharmaceuticals | September 3 Price is down by -6.2% in the last 24h. |
Armata Pharmaceuticals Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 4K | 30.3% | |
| Job Posts | 0 | N/A | |
| LinkedIn Employees | 74 | 5.7% | |
| Employee Recommend | 24 | 0% | |
| Business Outlook | 24 | 0% | |
| Sentiment | 100 | N/A | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 1 | 50.0% | |
| Stocktwits Mentions | 0 | N/A | |
| News Mentions | 0 | N/A | |
| Stocktwits Subscribers | 8K | 0% |
About Armata Pharmaceuticals (ARMP)
Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of specific bacteriophage therapies for the treatment of antibiotic-resistant infections worldwide. The company is headquartered in Marina del Rey, California.
| Price | $5.38 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $200M |
| Year Range | $3 – $15 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest Armata Pharmaceuticals News
View more → |
Armata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02July 20 - PRNewswire |
 |
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus BacteremiaJuly 13 - PRNewswire |
 |
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate UpdateMay 13 - PRNewswire |
|
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02May 7 - PRNewswire |
See Armata Pharmaceuticals’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for ARMP, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEArmata Pharmaceuticals Earnings & Financial Performance
View all earnings →Armata Pharmaceuticals Insider Trading Activity
View all →| No recent insider transactions on file. |
Armata Pharmaceuticals Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to Armata Pharmaceuticals
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Minerva NeurosciencesNERV |
$4.15 0.2% | $198M | 45 |
 |
Korro BioKRRO |
$13.81 5.7% | $203M | 40 |
 |
Voyager TherapeuticsVYGR |
$3.19 0.0% | $197M | 37 |
 |
Tonix PharmaceuticalsTNXP |
$11.87 3.3% | $204M | 59 |
 |
Neumora TherapeuticsNMRA |
$1.04 8.8% | $195M | 57 |
Explore Armata Pharmaceuticals Data
Frequently Asked Questions: Armata Pharmaceuticals (ARMP)
Armata Pharmaceuticals has an AltIndex AI Score of 46/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
46/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of Armata Pharmaceuticals (ARMP) stock is $5.38 with a market cap of $200M.
As of today, Armata Pharmaceuticals’s PE (Price to Earnings) ratio is —.
View the latest Armata Pharmaceuticals insider transactions to see recent buying and selling activity by company executives and directors.
Check the Armata Pharmaceuticals congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The ARMP stock price chart above shows Armata Pharmaceuticals’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full Armata Pharmaceuticals technical analysis for RSI, moving averages, and more.
See the stocks similar to Armata Pharmaceuticals section on this page for companies in the same industry ranked by market cap and AI Score.
